Cordis announced on 10 September the launch of its Incraft AAA Stent Graft System, an ultra-low profile device for use during endovascular aneurysm repair (EVAR) for patients suffering from infrarenal abdominal aortic aneurysms. The Incraft System is cleared for use and is now available in Europe and Canada. According to Cordis, the device is an advancement in the EVAR field and provides a new option for patients and physicians seeking a less invasive treatment approach for abdominal aortic aneurysms
Avinger has announced that John Pigott of Jobst Vascular Institute, Toledo, USA has enrolled the first patient in VISION. VISION is a global investigational device exemption (IDE) clinical trial, approved by the FDA, to evaluate Avinger’s Pantheris catheter for the treatment of peripheral artery disease
Data presented at the 26th World Congress of the International Union of Angiology (IUA), Sydney, Australia, highlights the benefit of ultrasound screening in detecting early signs of vascular disease in otherwise ‘low’ to ‘moderate’ risk asymptomatic individuals – with the potential to half the incidence of stroke and heart attacks
Endovascular repair of popliteal artery aneurysm provides successful aneurysm exclusion with good long-term patency, excellent limb salvage, and survival rates, according to a study published in the August 2014 edition of the European Journal of Vascular and Endovascular Surgery. At five years of follow-up, limb salvage was 98%, survival rate was 84% and mean sac volume shrinkage from 45.5mL to 23mL
Biotronik has announced the completion of patient enrolment in the superficial femoral artery (SFA) arm of its BIOFLEX-I clinical trial, an FDA-approved investigative device exemption (IDE) trial evaluating the use of self-expanding nitinol stents in treating peripheral artery disease. A total of 296 patients were successfully implanted with the Astron Pulsar and Pulsar-18 stents at 34 centres in the USA, Canada and Europe
Daisuke Kamoi, Nagoya Kyoritsu Hospital, Nagoya, Japan, reported on the first-in-man experience of angioscopy-guided chronic total occlusion techniques in peripheral arterial lesions at the EuroPCR congress (20–23 May, Paris, France). The system used in the study was the I-Light angioscopy system from iHeart Medical
Bristol‐Myers Squibb Company and Pfizer have announced that the European Commission has approved Eliquis (apixaban) for the treatment of deep vein thrombosis and pulmonary embolism, and the prevention of recurrent deep vein thrombosis and pulmonary embolism in adults. The European Commission approval applies to all European Union (EU) member states as well as Iceland and Norway. This approval broadens the clinical use for apixaban which is also approved for use in the EU for the prevention of venous thromboembolism (VTE) in adults who have undergone elective total hip or knee replacement surgery, and the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors
Numerous studies claim that in moderation, dark chocolate is good for our health. Now, a new study published in the Journal of the American Heart Association adds to the evidence, suggesting that it may help increase walking distance for people with peripheral artery disease.
A new driver of atherosclerosis has been identified by researchers at UT Southwestern Medical Center. This molecule, known as 27HC (27-hydroxycholesterol), has been found to exacerbate the development of the condition, and may prove to be a promising therapeutic target.
Los hombres mayores que fuman o que han fumado cien o más cigarrillos deben recibir pruebas de detección para un aneurisma aórtico abdominal, recomienda un panel de expertos en salud de Estados Unidos.
In a multicentre randomised trial, a silver alginate dressing failed to reduce wound complications in patients undergoing open lower limb procedures. The results were presented at the Society for Vascular Surgery Annual Meeting (5–7 June, Boston, USA).
Bristol-Myers Squibb Company and Pfizer have announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Eliquis (apixaban) be granted marketing authorisation for the treatment of deep vein thrombosis and pulmonary embolism, and the prevention of recurrent deep vein thrombosis and pulmonary embolism, in adults. The CHMP’s positive opinion will now be reviewed by the European Commission. The decision on whether to approve apixaban for this indication will be made by the European Commission and will be applicable to all European Union member states plus Iceland and Norway.
Lombard Medical exhibited its Aorfix endovascular stent graft system at the 18th international experts’ symposium, Critical Issues in Aortic Endografting, in Malmö, Sweden on 27–28 June 2014.
An analysis of the OVER trial presented at the Society for Vascular Surgery Vascular Annual Meeting (SVS, 5–7 June, Boston, USA) shows that the development of endoleaks were common in patients treated with endovascular aneurysm repair (EVAR) in the study, with an incidence of 31%. Wei Zhou, who presented the results of the analysis, said that 53% of the endoleaks seen in the trial resolved spontaneously.
Results from a feasibility study conducted in Italy indicate that ultrasound-enhanced paclitaxel delivery inhibits arterial smooth muscle proliferation after balloon angioplasty in peripheral arterial disease. Costantino Del Giudice, Department of Radiology, University Hospital Tor Vergata, Rome, Italy, spoke about the study at the EuroPCR congress (19–23 May, Paris, France).
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos